{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-122171","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.961599+00:00","generated_at":"2026-06-07T19:46:28.517955+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Pharma gets Nasdaq deficiency notice for bid price below $1.00","bullets":["Received Nasdaq deficiency letter on Nov 27, 2023 for bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days, until May 28, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by May 28, may be eligible for additional 180-day period if transfers to Nasdaq Capital Market.","Company may consider a reverse stock split to cure deficiency; no immediate effect on listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-122171","json":"https://secwatch.observer/filing/0001104659-23-122171.json","markdown":"https://secwatch.observer/filing/0001104659-23-122171.md","text":"https://secwatch.observer/filing/0001104659-23-122171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923122171/0001104659-23-122171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923122171/tm2331763d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:46:28.517955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"256d8fcfc40cb3394e21ba0b324ef517031bba01","claim":"RIGEL PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"November 27, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying Rigel that, for the last 30 consecutive business days, the bid price for Rigel’s common stock, par value $0.001 per share (the “Common Stock”), closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compli","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923122171/0001104659-23-122171-index.htm","confidence":0.97,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}